Valuation Edwards Lifesciences Corporation
Stocks
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
NYSE
23:00:03 21/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 89.79 USD | -0.04% |
|
-1.98% | +5.33% |
| 08-21 | Argus Adjusts Price Target on Edwards Lifesciences to $115 From $105, Maintains Buy Rating | MT |
| 08-17 | Becton Dickinson Names Gary Sorsher as Chief Quality Officer | MT |
Company Valuation: Edwards Lifesciences Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 80,883 | 46,128 | 46,246 | 43,663 | 49,471 | 51,755 | - | - |
| Change | - | -42.97% | 0.25% | -5.58% | 13.3% | 4.62% | - | - |
| Enterprise Value (EV) 1 | 80,616 | 45,956 | 45,198 | 40,285 | 45,843 | 48,124 | 46,560 | 44,744 |
| Change | - | -42.99% | -1.65% | -10.87% | 13.8% | 4.98% | -3.25% | -3.9% |
| P/E | 54.4x | 30.6x | 33.2x | 10.6x | 46.6x | 35.5x | 27.2x | 24.2x |
| PBR | 13.9x | 7.82x | 6.99x | 4.36x | 4.79x | 4.88x | 4.25x | 3.94x |
| PEG | - | 12.14x | -5.79x | 0x | -0.6x | 0.9x | 0.9x | 1.9x |
| Capitalization / Revenue | 15.5x | 8.57x | 7.7x | 8.03x | 8.15x | 7.66x | 6.97x | 6.33x |
| EV / Revenue | 15.4x | 8.54x | 7.53x | 7.41x | 7.56x | 7.12x | 6.27x | 5.47x |
| EV / EBITDA | 46.6x | 23.7x | 24.1x | 24.1x | 25.5x | 22.5x | 19.5x | 16.7x |
| EV / EBIT | 50.6x | 25.6x | 26.1x | 26.6x | 27.9x | 24.4x | 21.1x | 18x |
| EV / FCF | 57.3x | 47.2x | 47.9x | 139x | 34.3x | 56.7x | 28.9x | 24.6x |
| FCF Yield | 1.74% | 2.12% | 2.09% | 0.72% | 2.91% | 1.76% | 3.46% | 4.06% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 2.38 | 2.44 | 2.3 | 6.97 | 1.83 | 2.531 | 3.304 | 3.718 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 5,232 | 5,382 | 6,005 | 5,440 | 6,068 | 6,759 | 7,429 | 8,177 |
| EBITDA 1 | 1,729 | 1,936 | 1,879 | 1,670 | 1,800 | 2,137 | 2,384 | 2,687 |
| EBIT 1 | 1,594 | 1,796 | 1,734 | 1,514 | 1,644 | 1,971 | 2,212 | 2,484 |
| Net income 1 | 1,503 | 1,522 | 1,402 | 4,175 | 1,074 | 1,435 | 1,897 | 2,121 |
| Net Debt 1 | -267 | -172.7 | -1,048 | -3,378 | -3,628 | -3,631 | -5,195 | -7,011 |
| Reference price 2 | 129.55 | 74.61 | 76.25 | 74.03 | 85.25 | 89.79 | 89.79 | 89.79 |
| Nbr of stocks (in thousands) | 624,334 | 618,260 | 606,500 | 589,800 | 580,300 | 576,400 | - | - |
| Announcement Date | 1/26/22 A | 1/31/23 A | 2/6/24 A | 2/11/25 A | 2/10/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 35.48x | 7.12x | 22.52x | -.--% | 51.75B | ||
| 31.34x | 5.52x | 21.17x | 0.29% | 233B | ||
| 36.92x | 6.61x | 20.97x | 0.65% | 154B | ||
| 41.55x | 10.81x | 23.9x | -.--% | 134B | ||
| 18.8x | 3.82x | 12.41x | -.--% | 73B | ||
| 19.92x | 2.38x | 11.91x | 2.56% | 52.24B | ||
| 30.92x | 6.16x | 21.06x | 0.65% | 44.91B | ||
| 71.9x | 6.86x | 20.86x | -.--% | 40.35B | ||
| 16.02x | 1.83x | 10.25x | 0.21% | 33.8B | ||
| 20.1x | 5.58x | 14.4x | 1.15% | 33.4B | ||
| Average | 32.29x | 5.67x | 17.94x | 0.55% | 84.98B | |
| Weighted average by Cap. | 33.28x | 6.26x | 19.60x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- EW Stock
- Valuation Edwards Lifesciences Corporation
Select your edition
All financial news and data tailored to specific country editions
















